Chun Zhou1, Zhuxian Zhang1, Mengyi Liu1, Yuanyuan Zhang1, Panpan He1, Qinqin Li2, Di Xie1, Min Liang1, Guobao Wang1, Jing Nie1, Chengzhang Liu3, Yun Song4, Lishun Liu4, Binyan Wang2, Xiaobin Wang5, Xiping Xu1,2,4, Xianhui Qin6. 1. Division of Nephrology, Nanfang Hospital, Southern Medical University, National Clinical Research Center for Kidney Disease, State Key Laboratory of Organ Failure Research, Guangdong Provincial Institute of Nephrology, Guangdong Provincial Key Laboratory of Renal Failure Research, Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangdong Provincial Clinical Research Center for Kidney Disease, Guangzhou, 510515, China. 2. Institute of Biomedicine, Anhui Medical University, Hefei, 230032, China. 3. Shenzhen Evergreen Medical Institute, Shenzhen, 518057, China. 4. Beijing Advanced Innovation Center for Food Nutrition and Human Health, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing, 100083, China. 5. Department of Population, Family and Reproductive Health, Johns Hopkins University Bloomberg School of Public Health, 615 N. Wolfe Street, E4132, Baltimore, MD, 21205-2179, USA. 6. Division of Nephrology, Nanfang Hospital, Southern Medical University, National Clinical Research Center for Kidney Disease, State Key Laboratory of Organ Failure Research, Guangdong Provincial Institute of Nephrology, Guangdong Provincial Key Laboratory of Renal Failure Research, Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangdong Provincial Clinical Research Center for Kidney Disease, Guangzhou, 510515, China. pharmaqin@126.com.
Abstract
PURPOSE: Visceral adiposity index (VAI) is a reliable indicator for the distribution and function of adipose tissue in the body. The relation of VAI with new-onset type 2 diabetes and new-onset impaired fasting glucose (IFG) remains uncertain. We aimed to investigate the prospective relation of VAI with new-onset type 2 diabetes and new-onset IFG in Chinese hypertensive adults. METHODS: A total of 14,838 hypertensive adults free of type 2 diabetes at baseline were included from the China Stroke Primary Prevention Trial. The primary outcome was new-onset type 2 diabetes, defined as physician-diagnosed diabetes or use of glucose-lowering drugs during follow-up, or fasting glucose ≥ 7.0 mmol/L at the exit visit. The secondary outcome was new-onset IFG, defined as fasting glucose < 6.1 mmol/L at baseline, while fasting glucose ≥ 6.1 mmol/L and < 7.0 mmol/L at the exit visit. RESULTS: Over a median of 4.5 years' follow-up, 1612 (10.9%) participants developed type 2 diabetes. When VAI was categorized into quartiles, compared with participants in quartile 1-3 (< 2.80), significantly higher risk of new-onset type 2 diabetes (OR 1.30; 95% CI 1.08-1.56) and new-onset IFG (OR 1.28; 95% CI 1.08-1.52) was found in those in quartile 4 (≥ 2.80). Moreover, the positive associations were consistent in participants with or without single abnormal VAI components, including general obesity, abdominal obesity, elevated triglycerides and low high-density lipoprotein cholesterol (HDL-C) levels; or with different numbers of abnormal VAI components (all P interactions > 0.05). CONCLUSION: Our study suggested a positive relation of VAI with the risk of new-onset type 2 diabetes and new-onset IFG in Chinese hypertensive patients, independent of its components. LEVEL OF EVIDENCE: Level III, a well-designed cohort.
PURPOSE: Visceral adiposity index (VAI) is a reliable indicator for the distribution and function of adipose tissue in the body. The relation of VAI with new-onset type 2 diabetes and new-onset impaired fasting glucose (IFG) remains uncertain. We aimed to investigate the prospective relation of VAI with new-onset type 2 diabetes and new-onset IFG in Chinese hypertensive adults. METHODS: A total of 14,838 hypertensive adults free of type 2 diabetes at baseline were included from the China Stroke Primary Prevention Trial. The primary outcome was new-onset type 2 diabetes, defined as physician-diagnosed diabetes or use of glucose-lowering drugs during follow-up, or fasting glucose ≥ 7.0 mmol/L at the exit visit. The secondary outcome was new-onset IFG, defined as fasting glucose < 6.1 mmol/L at baseline, while fasting glucose ≥ 6.1 mmol/L and < 7.0 mmol/L at the exit visit. RESULTS: Over a median of 4.5 years' follow-up, 1612 (10.9%) participants developed type 2 diabetes. When VAI was categorized into quartiles, compared with participants in quartile 1-3 (< 2.80), significantly higher risk of new-onset type 2 diabetes (OR 1.30; 95% CI 1.08-1.56) and new-onset IFG (OR 1.28; 95% CI 1.08-1.52) was found in those in quartile 4 (≥ 2.80). Moreover, the positive associations were consistent in participants with or without single abnormal VAI components, including general obesity, abdominal obesity, elevated triglycerides and low high-density lipoprotein cholesterol (HDL-C) levels; or with different numbers of abnormal VAI components (all P interactions > 0.05). CONCLUSION: Our study suggested a positive relation of VAI with the risk of new-onset type 2 diabetes and new-onset IFG in Chinese hypertensive patients, independent of its components. LEVEL OF EVIDENCE: Level III, a well-designed cohort.
Authors: Caroline E Dale; Ghazaleh Fatemifar; Tom M Palmer; Jon White; David Prieto-Merino; Delilah Zabaneh; Jorgen E L Engmann; Tina Shah; Andrew Wong; Helen R Warren; Stela McLachlan; Stella Trompet; Max Moldovan; Richard W Morris; Reecha Sofat; Meena Kumari; Elina Hyppönen; Barbara J Jefferis; Tom R Gaunt; Yoav Ben-Shlomo; Ang Zhou; Aleksandra Gentry-Maharaj; Andy Ryan; Renée de Mutsert; Raymond Noordam; Mark J Caulfield; J Wouter Jukema; Bradford B Worrall; Patricia B Munroe; Usha Menon; Chris Power; Diana Kuh; Debbie A Lawlor; Steve E Humphries; Dennis O Mook-Kanamori; Naveed Sattar; Mika Kivimaki; Jacqueline F Price; George Davey Smith; Frank Dudbridge; Aroon D Hingorani; Michael V Holmes; Juan P Casas Journal: Circulation Date: 2017-05-12 Impact factor: 29.690
Authors: Ian J Neeland; Aslan T Turer; Colby R Ayers; Tiffany M Powell-Wiley; Gloria L Vega; Ramin Farzaneh-Far; Scott M Grundy; Amit Khera; Darren K McGuire; James A de Lemos Journal: JAMA Date: 2012-09-19 Impact factor: 56.272
Authors: Caroline S Fox; Joseph M Massaro; Udo Hoffmann; Karla M Pou; Pal Maurovich-Horvat; Chun-Yu Liu; Ramachandran S Vasan; Joanne M Murabito; James B Meigs; L Adrienne Cupples; Ralph B D'Agostino; Christopher J O'Donnell Journal: Circulation Date: 2007-06-18 Impact factor: 29.690